FDA scrutinizes peptide safety as industry insiders join expert panel

The FDA is re-examining the safety and effectiveness of popular peptide injections in a July meeting. This follows previous rejections of several peptide ingredients over safety concerns. The discussion comes as peptides gain popularity among athletes and celebrities for claimed benefits like muscle growth and injury recovery. Peptides have become a wellness trend, promoted for muscle building, healing, and anti-ageing. However, scientific evidence supporting these claims remains limited. Sellers often bypass regulations by marketing products as 'for research use only'.

The new FDA panel includes members with direct ties to the peptide industry. Dr. Haleem Mohammed and Dr. Gabriel Alizaidy run clinics or businesses specialising in peptides. Tennessee state senator and pharmacist Bobby Harshbarger also sits on the panel, with his own industry connections.

This differs from earlier panels, which consisted mainly of academics and researchers. The FDA has previously warned about the risks of peptides like BPC-157 and TB-500, which are banned as doping substances in international sports.

Robert F. Kennedy Jr. has publicly supported peptides and used them for personal recovery. He and his allies have criticised federal expert panels for alleged conflicts of interest and have pushed for changes in similar bodies, including the CDC’s vaccine panel. The July meeting will reassess peptide safety amid growing industry influence on the panel. The FDA’s decision could impact regulation and public trust in these widely marketed substances. Previous warnings about doping risks and unproven benefits remain a key concern.